What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
The contraindications relate to both the semaglutide and cyanocobalamin components, and careful consideration must be given to each ingredients specific safety profile and potential risks
Subcutaneous means that an injection is given into the fat between your skin and muscle (usually on your thigh or stomach)
Hematologic surprises: isolated reports of polycythemia B12 supports red blood cell production
Hydroxocobalamin: Professional patient advice
Yes MIC lipotropic compounds (Methionine, Inositol, Choline) are recognized nutrients with well-characterized safety profiles